Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

HUTCHMED (H7T1) Stock Price & Analysis

1 Followers

H7T1 Stock Chart & Stats

€12.90-€0.40(-3.01%)
At close: 5:30 PM GMT+1
€10€12.5€15€17.5Mar 20Mar 11Feb 20Feb 25
Day’s Range
EUR 12.90 - EUR 12.90
52-Week Range
EUR 8.45 - EUR 13.50
Previous Close
EUR 13.30
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 2.36B
Enterprise Value
EUR 612.26M
Total Cash (Recent Filing)
EUR 1.38B
Total Debt (Recent Filing)
EUR 94.51M
Price to Earnings (P/E)
160.4
Beta
0.36
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
0.18
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage and a sizable equity base give HUTCHMED financial flexibility to fund development, support commercialization, and absorb operating volatility. The conservative capital structure also reduces interest-related pressure and preserves capacity for strategic investment over the next several quarters.

Recent Cash-flow Improvement

The return to positive operating and free cash flow is a constructive sign for internal funding capacity and liquidity. If maintained, stronger cash conversion could reduce reliance on external financing while supporting continued investment in the company’s medicines and development pipeline.

TTM Revenue Growth

Modest TTM revenue growth indicates that HUTCHMED’s commercial products and collaboration activities are still generating expansion in the latest period. Continued top-line progress would provide a foundation for operating leverage if product uptake and revenue scale improve over time.

Bears Say

Negative Core Profitability

Persistently negative EBIT and EBITDA margins show that core operations are not yet producing sustainable operating profits. This limits internally generated funding, leaves results sensitive to development and commercialization costs, and makes durable earnings improvement dependent on better scale or cost performance.

Volatile Cash Generation

Large swings in free cash flow make financial planning and investment funding less predictable, even after the latest improvement. Volatility can constrain long-term capital allocation and increase the importance of maintaining a strong balance sheet while the business advances its portfolio.

Earnings Quality Risk

Strong reported net income alongside negative operating results indicates that earnings may not currently reflect repeatable performance from the underlying business. This weakens confidence in earnings durability and means future results could depend more heavily on non-operating items or timing effects.

HUTCHMED News

H7T1 FAQ

What was HUTCHMED’s price range in the past 12 months?
HUTCHMED lowest stock price was €8.45 and its highest was €13.50 in the past 12 months.
What is HUTCHMED’s market cap?
HUTCHMED’s market cap is €2.36B.
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 109 days.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Jul 30, 2026. The company reported €0.09 earnings per share for the quarter, missing the consensus estimate of €0.13 by -€0.04.
Is HUTCHMED overvalued?
According to Wall Street analysts HUTCHMED’s price is currently Undervalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is 0.18.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,467,030 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of €0.09 in its last earnings report, missing expectations of €0.13. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of HUTCHMED?
Hedge funds hold HUTCHMED shares: the largest hedge-fund position in HUTCHMED is 502,720,973 shares, and hedge funds decreased their holdings by 110.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology